• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why RLX Technology Shares Are Gaining Today

    3/15/24 9:14:30 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    RLX Technology Inc. (NYSE:RLX) shares are trading higher in the premarket session on Friday.

    The company reported fourth-quarter adjusted earnings per ADS of $0.046, beating the analyst consensus of $0.02. 

    Quarterly revenue of $73.31 million beats the street view of $66.52 million.

    Gross margin was 23.7% in the fourth quarter of 2023, compared with 43.6% in the same period of 2022.

    The decrease was primarily due to the imposition of a 36% excise tax, and an unfavorable change in revenue mix.

    For the fourth quarter, net cash generated from operating activities was $43.0 million.

    As of December 31, 2023, the company had cash and equivalents worth $2.132 billion.

    “By acquiring and integrating resources across diverse markets, we can create powerful synergies and elevate operational efficiency, enhancing our global competitiveness,” said Ying (Kate) Wang, Co-founder, Chairperson of the Board of Directors, and CEO of RLX Technology. 

    “For our domestic business in China, we remain committed to optimizing our product portfolios while combatting illegal products that still weigh on legitimate players’ sales, advocating for a responsible and well-regulated e-vapor industry.”

    Price Action: RLX shares are trading higher by 7.22% premarket to $2.09 on the last check Friday.

    Get the next $RLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    12/31/25 6:03:48 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    11/14/25 6:02:26 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    8/22/25 7:09:03 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RLX Technology Extends US$500 Million Share Repurchase Program

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary share

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care